Role of advanced glycation end products in cardiovascular disease

doi:10.4330/wjc.v4.i4.90

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15644)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series.

Item

Count

PDF

946

HTML

14297

Figures (1-4)

401

Sum=15644

Apr 26, 2012 (publication date) through Nov 15, 2024

Times Cited of This Article

Times Cited (254)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Cardiol. Apr 26, 2012; 4(4): 90-102
Published online Apr 26, 2012. doi: 10.4330/wjc.v4.i4.90

Full Size Figure Download Figure

Figure 2 Effects of advanced glycation end products on extracellular matrix proteins. In extracellular matrix, advanced glycation end products (AGEs) form on different molecules as collagen, laminin and elastin. This alters the physiological properties of the matrix and increases its stiffness. AGEs upregulate transforming growth factor (TGF)-β that increases the production of extracellular matrix components by binding to its receptor.

Citation: Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol 2012; 4(4): 90-102
URL: https://www.wjgnet.com/1949-8462/full/v4/i4/90.htm
DOI: https://dx.doi.org/10.4330/wjc.v4.i4.90